Related Experiment Video
Updated: May 1, 2026

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
Published on: April 4, 2025
Treatment of acute kidney injury with cast nephropathy
Abstract:
Nearly 50% of patients with multiple myeloma develop renal disease; acute kidney injury (AKI) from cast nephropathy, or "myeloma kidney" is the most common type. Development of AKI is associated with worse 1-year survival and reduces the therapeutic options available to patients. Therefore, there is a great need to develop more effective therapies. Cast nephropathy is due to the interaction and aggregation of filtered free light chains (FLCs) and Tamm- Horsfall protein (THP) causing intratubular obstruction and damage. The key to treating cast nephropathy is rapid lowering of FLCs as this correlates with renal recovery. Newer chemotherapy agents lower FLCs and have been referred to as "renoprotective". However there remains great interest in using various extracorporeal therapies to remove serum FLCs. Initially, therapeutic plasma exchange (TPE) was thought to improve renal outcomes in cast nephropathy based on small trials. The largest randomized trial of TPE, however, failed to show any benefit. A newer technique is extended high cut-off hemodialysis (HCO-HD). This modality uses a high molecular weight cut-off filter to remove FLCs. To date, trials with HCO-HD in patients with cast nephropathy have been encouraging. However, there are no randomized trials demonstrating the benefit of HCOHD when used in addition to newer chemotherapeutic regimens. Until these studies are available, HCO-HD cannot be recommended as standard of care.
Insights
Multiple myeloma patients with kidney injury need better treatments. While newer chemotherapy is promising, extended high cut-off hemodialysis (HCO-HD) shows potential for removing harmful proteins, but requires more study.
Area of Science:
- Nephrology
- Oncology
- Renal Medicine
Background:
- Multiple myeloma frequently causes renal disease, primarily acute kidney injury (AKI) from cast nephropathy.
- AKI in myeloma significantly worsens patient survival and limits treatment options, highlighting the need for effective therapies.
- Cast nephropathy arises from filtered free light chains (FLCs) and Tamm-Horsfall protein (THP) aggregation, causing tubular obstruction.
Purpose of the Study:
- To review the role of extracorporeal therapies in managing cast nephropathy in multiple myeloma.
- To evaluate the efficacy of extended high cut-off hemodialysis (HCO-HD) compared to previous methods like therapeutic plasma exchange (TPE).
Main Methods:
- Review of existing literature on extracorporeal therapies for myeloma kidney.
- Analysis of trials involving therapeutic plasma exchange (TPE) and extended high cut-off hemodialysis (HCO-HD).
Main Results:
- Therapeutic plasma exchange (TPE) has not demonstrated clear renal benefits in larger trials.
- Extended high cut-off hemodialysis (HCO-HD) shows encouraging results in preliminary studies for removing FLCs.
- No randomized trials currently confirm HCO-HD's benefit when added to modern chemotherapy regimens.
Conclusions:
- Rapid reduction of FLCs is crucial for renal recovery in cast nephropathy.
- While HCO-HD is a promising extracorporeal therapy for FLC removal, its role as standard care alongside chemotherapy is not yet established.
- Further randomized trials are necessary to validate the benefits of HCO-HD in multiple myeloma patients with renal disease.
Related Concept Videos
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury VI: Nursing Management
Chronic Kidney Disease III: Interprofessional Care
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury I: Introduction

